IRIS

Bromobenzene

CASRN 108-86-1 | DTXSID5024637

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (27 pp, 243 K) Last Updated: 09/30/2009

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Hepatic 8 x 10 -3
(Chronic)
Hepatocellular cytomegaly in male B6C3F1 mice BMDL 10 : 24.1
mg/kg-day
3000 Low/Medium
Hepatic 2 x 10 -2
(Subchronic)
Hepatocellular cytomegaly in male B6C3F1 mice BMDL 10 : 24.1
mg/kg-day
1000 Medium

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (27 pp, 243 K) Last Updated: 09/30/2009

System RfC (mg/m3) Basis PoD Composite UF Confidence
Hepatic 6 x 10 -2
(Chronic)
Hepatocellular cytomegaly in female B6C3F1 mice BMCL 10 : 63
mg/m3
1000 Low/Medium
Hepatic 2 x 10 -1
(Subchronic)
Hepatocellular cytomegaly in female B6C3F1 mice BMCL 10 (HEC): 63
mg/m3
300 Medium

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (27 pp, 243 K) Last Updated: 09/30/2009

WOE Characterization Framework for WOE Characterization
Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of bromobenzene.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (27 pp, 243 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (27 pp, 243 K)

Not assessed under the IRIS Program.

Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.

Contact Us to ask a question, provide feedback or report a problem.